Tokyo, Jan 7, 2013 (JCN) - Takara Bio and its collaborators, University of Pennsylvania and Drexel University College of Medicine have initiated a Phase 1 clinical trial in its program for HIV-1 infections.
Takara Bio has developed an investigational retroviral technology for HIV-1 gene therapy, in which MazF, an endoribonuclease from Escherichia coli, confers resistance to a broad-spectrum of HIV-1 strains on CD4+ T cells.
The Regulatory Sponsor of this study is Carl H. June, M.D., Professor of Pathology and Laboratory Medicine at the University of Pennsylvania. The Principal Investigator of the study is Jeffrey M. Jacobson, M.D., Chief of the Division of Infectious Diseases and HIV Medicine and Professor of Medicine, Microbiology and Immunology Division at Drexel University College of Medicine.
The MazF retroviral vector for this study is manufactured at the GMP compliant Center for Cell and Gene Therapy Facility of Takara Bio (Kusatsu, Shiga, Japan). The patients' CD4+ T cells will be modified with MazF retroviral vector at the GMP compliant Cell and Vaccine Production Facility at the University of Pennsylvania.
In this clinical trial, the patients will be monitored for safety, tolerability and immunogenicity of the autologous CD4+ T cells modified with the MazF endoribonuclease for six months. The estimated total enrollment is twelve subjects, six in each of the Cohorts 1 and 2.
Copyright © 2013 JCN. All rights reserved. A division of Japan Corporate News Network KK.
 Company Profile |  Print |  Alerts
|
 |
|
Takara Bio Initiates Phase 1 HIV Gene Therapy Clinical Trial
(Jan 7, 2013)
|
|
|
Takara Bio Submits IND Application for HIV-1 Gene Therapy to the FDA
(Mar 23, 2012)
|
|
|
Takara Bio and Tianjin Medical University in Gene Therapy Project
(Aug 3, 2011)
|
|
|
Takara Bio RetroNectin to UCLA for TCR-gene Therapy Clinical Trials in Advanced Melanoma
(Dec 18, 2008)
|
|
|
Takara Bio Announces Start of Clinical Research of Cancer Immunotherapy using RetroNectin(R) Expansion Culture System at Tianjin Cancer Institute & Hospital, China
(May 2, 2008)
|
|
|
Takara Bio Grants Transgenomic License for LA-PCR Technology
(May 7, 2007)
|
|
|
ViroMed Obtains Clinical Trial Approval of Gene Therapy Treatment for Chronic Granulomatosis
(Jan 11, 2007)
|
|
|
Takara Bio's RetroNect Used in Australia for Gene Therapy Clinical Trials of Multiple Myeloma
(Dec 18, 2006)
|
|
|
Takara Bio Offers Drug for Treatment of Chronic Lymphatic Leukemia
(Sept 7, 2006)
|
|
|
Takara Bio Offers Drug for Treatment of Chronic Lymphatic Leukemia
(Sept 7, 2006)
|
|
|
|
|
|
|
Fujifilm Initiates Phase I Clinical Trial in Japan for Anticancer Agent FF-10501 (June 7, 2013)
|
|
|
Otsuka Launches First Skin Patch Treatment for Parkinson's Disease and Restless Legs Syndrome (Feb 22, 2013)
|
|
|
Teijin Launches Polyester Curtain Fabric with Enhanced Pollen-trapping (Feb 21, 2013)
|
|
|
Toyota Tsusho Opens Medical Clinic in Thai Plant (Feb 18, 2013)
|
|
|
Daiichi Sankyo Develops Nucleic Acid Treatment for Duchenne Muscular Dystrophy (Feb 15, 2013)
|
|
|
Dainippon Sumitomo Pharma Opens Subsidiary in Singapore (Jan 22, 2013)
|
|
|
Teijin and InCube Labs Enter Strategic Partnership in Healthcare Business (Jan 22, 2013)
|
|
|
Chugai Grants Debiopharm Group Exclusive Worldwide License for Anti-cancer Agent (Jan 9, 2013)
|
|
|
Takara Bio Initiates Phase 1 HIV Gene Therapy Clinical Trial (Jan 7, 2013)
|
|
|
Kobe University, KNC Labs and Dainippon Sumitomo to Research Anti-cancer Agent (Dec 28, 2012)
|
More Medical news...
|
|
